Capricor Therapeutics Inc
CAPR29.680USD
+0.780+2.70%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.36BMarket Cap
LossP/E TTM
More Details of Capricor Therapeutics Inc Company
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. It leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.
Capricor Therapeutics Inc Info
Ticker SymbolCAPR
Company nameCapricor Therapeutics Inc
IPO dateJun 04, 2002
CEOMarban (Linda)
Number of employees160
Security typeOrdinary Share
Fiscal year-endJun 04
Address10865 Road to the Cure
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone13103583200
Websitehttps://capricor.com/
Ticker SymbolCAPR
IPO dateJun 04, 2002
CEOMarban (Linda)
Company Executives of Capricor Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Linda Marban, Ph.D.
Dr. Linda Marban, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
212.02K
+6.26%
Mr. David B. Musket
Mr. David B. Musket
Independent Director
Independent Director
88.79K
--
Mr. Anthony Bergmann
Mr. Anthony Bergmann
Chief Financial Officer
Chief Financial Officer
8.22K
+43.68%
Dr. Michael Binks, M.D.
Dr. Michael Binks, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Frank I. Litvack, M.D.
Dr. Frank I. Litvack, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. George W. Dunbar, Jr.
Mr. George W. Dunbar, Jr.
Independent Director
Independent Director
--
--
Dr. Paul Auwaerter, M.D.
Dr. Paul Auwaerter, M.D.
Independent Director
Independent Director
--
--
Ms. Karimah Es Sabar
Ms. Karimah Es Sabar
Independent Director
Independent Director
--
--
Ms. Karen G. Krasney, J.D.
Ms. Karen G. Krasney, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
--
--
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Linda Marban, Ph.D.
Dr. Linda Marban, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
212.02K
+6.26%
Mr. David B. Musket
Mr. David B. Musket
Independent Director
Independent Director
88.79K
--
Mr. Anthony Bergmann
Mr. Anthony Bergmann
Chief Financial Officer
Chief Financial Officer
8.22K
+43.68%
Dr. Michael Binks, M.D.
Dr. Michael Binks, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Frank I. Litvack, M.D.
Dr. Frank I. Litvack, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. George W. Dunbar, Jr.
Mr. George W. Dunbar, Jr.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Nippon Shinyaku Co Ltd
15.51%
BlackRock Institutional Trust Company, N.A.
5.82%
The Vanguard Group, Inc.
4.83%
Geode Capital Management, L.L.C.
2.10%
State Street Investment Management (US)
1.75%
Other
69.99%
Shareholders
Shareholders
Proportion
Nippon Shinyaku Co Ltd
15.51%
BlackRock Institutional Trust Company, N.A.
5.82%
The Vanguard Group, Inc.
4.83%
Geode Capital Management, L.L.C.
2.10%
State Street Investment Management (US)
1.75%
Other
69.99%
Shareholder Types
Shareholders
Proportion
Investment Advisor
16.23%
Corporation
15.51%
Investment Advisor/Hedge Fund
8.08%
Hedge Fund
4.60%
Research Firm
1.99%
Individual Investor
1.28%
Bank and Trust
0.98%
Pension Fund
0.17%
Venture Capital
0.12%
Other
51.03%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
267
14.69M
38.00%
+7.56K
2025Q3
269
14.68M
44.13%
+675.04K
2025Q2
254
13.97M
53.43%
-4.77M
2025Q1
240
18.64M
48.30%
-3.42M
2024Q4
201
17.56M
26.28%
+9.11M
2024Q3
144
8.40M
24.51%
+1.94M
2024Q2
116
6.44M
24.20%
+1.62M
2024Q1
88
4.82M
22.54%
-2.30M
2023Q4
70
4.02M
18.98%
-1.52M
2023Q3
72
5.55M
11.71%
+2.91M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Nippon Shinyaku Co Ltd
7.09M
15.51%
+4.94M
+230.41%
Sep 20, 2024
BlackRock Institutional Trust Company, N.A.
2.73M
5.96%
+34.47K
+1.28%
Jun 30, 2025
The Vanguard Group, Inc.
2.30M
5.02%
+41.09K
+1.82%
Jun 30, 2025
Geode Capital Management, L.L.C.
963.08K
2.11%
+61.70K
+6.85%
Jun 30, 2025
State Street Investment Management (US)
1.47M
3.21%
-376.12K
-20.41%
Jun 30, 2025
Pier Capital, LLC
367.72K
0.8%
+13.54K
+3.82%
Jun 30, 2025
Morgan Stanley & Co. LLC
463.03K
1.01%
-272.07K
-37.01%
Jun 30, 2025
Two Sigma Investments, LP
216.46K
0.47%
+91.50K
+73.23%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
0.36%
Virtus LifeSci Biotech Clinical Trials ETF
0.32%
ALPS Medical Breakthroughs ETF
0.12%
iShares Micro-Cap ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
View more
iShares Neuroscience and Healthcare ETF
Proportion0.36%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.32%
ALPS Medical Breakthroughs ETF
Proportion0.12%
iShares Micro-Cap ETF
Proportion0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.02%
ProShares UltraPro Russell2000
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Capricor Therapeutics Inc?
The top five shareholders of Capricor Therapeutics Inc are:
Nippon Shinyaku Co Ltd holds 7.09M shares, accounting for 15.51% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.73M shares, accounting for 5.96% of the total shares.
The Vanguard Group, Inc. holds 2.30M shares, accounting for 5.02% of the total shares.
Geode Capital Management, L.L.C. holds 963.08K shares, accounting for 2.11% of the total shares.
State Street Investment Management (US) holds 1.47M shares, accounting for 3.21% of the total shares.
Nippon Shinyaku Co Ltd holds 7.09M shares, accounting for 15.51% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.73M shares, accounting for 5.96% of the total shares.
The Vanguard Group, Inc. holds 2.30M shares, accounting for 5.02% of the total shares.
Geode Capital Management, L.L.C. holds 963.08K shares, accounting for 2.11% of the total shares.
State Street Investment Management (US) holds 1.47M shares, accounting for 3.21% of the total shares.
What are the top three shareholder types of Capricor Therapeutics Inc?
The top three shareholder types of Capricor Therapeutics Inc are:
Nippon Shinyaku Co Ltd
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Nippon Shinyaku Co Ltd
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
How many institutions hold shares of Capricor Therapeutics Inc (CAPR)?
As of 2025Q4, 267 institutions hold shares of Capricor Therapeutics Inc, with a combined market value of approximately 14.69M, accounting for 38.00% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -6.13%.
What is the biggest source of revenue for Capricor Therapeutics Inc?
In --, the -- business generated the highest revenue for Capricor Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
